Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab, targeting inflammation, reduced the risk of death
Peter Smith, Duke University Medical Center, Durham, NCLate Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006The drug pexelizumab, targeting inflammation, reduced the risk of death among patients about to have coronary artery by-pass grafting in the PRIMOCABG-II study. Peter Smith of Duke University told the ACC about his group’s findings.
Related Episodes
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,
Routine Angioplasty Recommended After Thrombolysis
Warren Cantor Tony Gershlick REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction Warren Cantor, University of Toronto COMMENT: Tony Gershlick, Leicester
